Variables | Outcomes | Multivariate analysis | |
---|---|---|---|
HR (95% CI) | P-value | ||
Age at diagnosis (ref: < 65.0 years) Age ≥ 65.0 years | PFS | 1.17 (0.50–2.71) | 0.717 |
OS | 3.04 (0.62–14.93) | 0.169 | |
CSS | 4.27 (0.45–40.00) | 0.204 | |
Gleason score at diagnosis (ref: 6≤ G ≤ 7) Gleason score ≥ 8 | PFS | 0.62 (0.25–1.58) | 0.317 |
OS | 1.70 (0.39–7.46) | 0.483 | |
CSS | 3.02 (0.43–20.83) | 0.265 | |
Total prostate-specific antigen (ng/ml) (ref: < 20) PSA ≥ 20 | PFS | 1.06 (0.46–2.48) | 0.887 |
OS | 1.32 (0.29–6.06) | 0.721 | |
CSS | 1.20 (0.12–11.76) | 0.878 | |
Pathological T stage at diagnosis (ref: T2) T3,4 | PFS | 3.53 (1.39–9.01) | 0.008 |
OS | 0.72 (0.15–3.50) | 0.682 | |
CSS | 0.98 (0.10–9.35) | 0.987 | |
Pathological N stage at diagnosis (ref: N0) N1 | PFS | 1.75 (0.73–4.18) | 0.210 |
OS | 1.92 (0.46–8.06) | 0.371 | |
CSS | 0.81 (0.08–8.62) | 0.862 | |
AR-V7-positive (ref: AR-V7-negative) | PFS | 3.76 (1.63–8.70) | 0.002 |
OS | 4.81 (1.28–17.86) | 0.020 | |
CSS | 9.17 (1.48–55.56) | 0.017 | |
R1(ref: R0) | PFS | 2.02 (0.80–5.08) | 0.135 |
OS | 1.79 (0.38–8.47) | 0.465 | |
CSS | 0.51 (0.04–7.35) | 0.620 |